Targeting inflammation to reduce 90-day and 1-year postoperative severe morbidity in patients with unfavorable inflammatory profile undergoing oncologic surgery (POST CARE Trial)

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515333-14-03

Enrollment

Registered

2025-12-17

Start date

Unknown

Completion date

Unknown

Last updated

2025-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients scheduled for major surgery for oncologic indication

Brief summary

test the clinical efficacy and the safety of the experimental treatment

Interventions

DRUGAcido Acetilsalicilico Teva Italia 100 mg compresse gastroresistenti

DRUGTora-Dol 30 mg/ml soluzione iniettabile

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
test the clinical efficacy and the safety of the experimental treatment	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026